Apricus Biosciences Company Profile (NASDAQ:APRI)

About Apricus Biosciences (NASDAQ:APRI)

Apricus Biosciences logoApricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company's drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud's phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:APRI
  • CUSIP: N/A
  • Web: www.apricusbio.com
Capitalization:
  • Market Cap: $21.48 million
  • Outstanding Shares: 12,783,000
Average Prices:
  • 50 Day Moving Avg: $1.52
  • 200 Day Moving Avg: $1.45
  • 52 Week Range: $0.26 - $4.07
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 1.13
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $5.76 million
  • Price / Sales: 3.73
  • Book Value: $0.51 per share
  • Price / Book: 3.29
Profitability:
  • EBIDTA: ($10,050,000.00)
  • Net Margins: -128.02%
  • Return on Assets: -91.93%
Debt:
  • Current Ratio: 4.70%
  • Quick Ratio: 4.70%
Misc:
  • Average Volume: 451,072 shs.
  • Beta: 0.55
  • Short Ratio: 3.14
 

Frequently Asked Questions for Apricus Biosciences (NASDAQ:APRI)

What is Apricus Biosciences' stock symbol?

Apricus Biosciences trades on the NASDAQ under the ticker symbol "APRI."

How were Apricus Biosciences' earnings last quarter?

Apricus Biosciences, Inc (NASDAQ:APRI) announced its earnings results on Wednesday, August, 2nd. The company reported ($0.15) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.01. View Apricus Biosciences' Earnings History.

When will Apricus Biosciences make its next earnings announcement?

Apricus Biosciences is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Apricus Biosciences.

Where is Apricus Biosciences' stock going? Where will Apricus Biosciences' stock price be in 2017?

2 analysts have issued 1-year target prices for Apricus Biosciences' shares. Their predictions range from $4.50 to $4.50. On average, they expect Apricus Biosciences' stock price to reach $4.50 in the next year. View Analyst Ratings for Apricus Biosciences.

Who are some of Apricus Biosciences' key competitors?

Who are Apricus Biosciences' key executives?

Apricus Biosciences' management team includes the folowing people:

  • Kleanthis G. Xanthopoulos Ph.D., Chairman of the Board
  • Richard W. Pascoe, Chief Executive Officer, Principal Accounting Officer, Secretary, Director
  • Brian T. Dorsey, Senior Vice President, Chief Development Officer
  • Paul V. Maier, Independent Director
  • Rusty Ray, Independent Director
  • Sandford D. Smith, Independent Director
  • Wendell Wierenga Ph.D., Independent Director

Who owns Apricus Biosciences stock?

Apricus Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.19%). View Institutional Ownership Trends for Apricus Biosciences.

Who sold Apricus Biosciences stock? Who is selling Apricus Biosciences stock?

Apricus Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for Apricus Biosciences.

How do I buy Apricus Biosciences stock?

Shares of Apricus Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Apricus Biosciences' stock price today?

One share of Apricus Biosciences stock can currently be purchased for approximately $1.68.


MarketBeat Community Rating for Apricus Biosciences (NASDAQ APRI)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  79 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  152
MarketBeat's community ratings are surveys of what our community members think about Apricus Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Apricus Biosciences (NASDAQ:APRI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.50 (167.86% upside)

Analysts' Ratings History for Apricus Biosciences (NASDAQ:APRI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/5/2017HC WainwrightReiterated RatingBuy$4.50MediumView Rating Details
4/26/2017Rodman & RenshawInitiated CoverageBuy -> BuyLowView Rating Details
3/15/2016Taglich BrothersLower Price TargetSpeculative Buy$4.25 -> $2.95N/AView Rating Details
3/11/2016Dawson JamesReiterated RatingBuyN/AView Rating Details
12/9/2015Sterne Agee CRTDowngradeBuy -> NeutralN/AView Rating Details
11/6/2015Roth CapitalDowngradeBuy -> Neutral$1.50N/AView Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for Apricus Biosciences (NASDAQ:APRI)
Earnings by Quarter for Apricus Biosciences (NASDAQ:APRI)
Earnings History by Quarter for Apricus Biosciences (NASDAQ APRI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.15)N/AView Earnings Details
8/2/2017Q2 2017($0.16)($0.15)ViewListenView Earnings Details
5/11/2017Q1 2017$1.25$1.04$12.00 millionViewN/AView Earnings Details
3/13/2017Q4 2016($0.15)($0.04)$3.44 million$0.40 millionViewN/AView Earnings Details
11/8/2016Q316($0.60)($0.19)$1.91 million$4.30 millionViewListenView Earnings Details
8/4/2016Q216($0.08)($0.05)$1.78 million$0.46 millionViewListenView Earnings Details
5/9/2016Q116($0.09)($0.09)$0.83 million$0.63 millionViewN/AView Earnings Details
3/9/2016Q415($0.11)($0.05)$1.81 million$2.60 millionViewListenView Earnings Details
11/5/2015Q315($0.11)($0.10)$1.42 million$1.30 millionViewListenView Earnings Details
8/5/2015Q2($0.13)($0.10)$0.70 million$0.46 millionViewListenView Earnings Details
5/11/2015Q1($0.10)($0.13)$0.95 million$0.48 millionViewListenView Earnings Details
3/16/2015Q4($0.12)($0.09)$0.67 million$1.91 millionViewListenView Earnings Details
11/10/2014Q314($0.09)($0.08)$1.23 million$1.90 millionViewN/AView Earnings Details
5/12/2014Q114($0.03)($0.09)$2.83 millionViewN/AView Earnings Details
3/17/2014Q212($0.06)($0.04)$2.00 million$0.36 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Apricus Biosciences (NASDAQ:APRI)
2017 EPS Consensus Estimate: ($0.06)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.04)($0.04)($0.04)
Q2 20171($0.01)($0.01)($0.01)
Q3 20171($0.02)($0.02)($0.02)
Q4 20171$0.01$0.01$0.01
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Apricus Biosciences (NASDAQ:APRI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Apricus Biosciences (NASDAQ:APRI)
Insider Ownership Percentage: 3.55%
Institutional Ownership Percentage: 15.27%
Insider Trades by Quarter for Apricus Biosciences (NASDAQ:APRI)
Institutional Ownership by Quarter for Apricus Biosciences (NASDAQ:APRI)
Insider Trades by Quarter for Apricus Biosciences (NASDAQ:APRI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/31/2017Alexander J DennerMajor ShareholderBuy6,104$1.63$9,949.52View SEC Filing  
3/3/2016Alexander J DennerMajor ShareholderBuy6,647,728$0.88$5,850,000.64View SEC Filing  
1/12/2016Alexander J DennerMajor ShareholderBuy1,306,819$0.88$1,150,000.72View SEC Filing  
12/29/2014Brian DorseyInsiderBuy10,000$1.05$10,500.00View SEC Filing  
12/22/2014Richard W PascoeCEOBuy10,000$1.02$10,200.00View SEC Filing  
10/23/2014Sandford D SmithDirectorBuy26,500$1.57$41,605.00View SEC Filing  
1/3/2014Leonard A OppenheimDirectorSell15,212$2.49$37,877.88View SEC Filing  
12/26/2013Kleanthis G XanthopoulosDirectorSell17,184$2.55$43,819.20View SEC Filing  
6/21/2013Kleanthis G XanthopoulosDirectorSell2,864$2.52$7,217.28View SEC Filing  
5/23/2013Richard W PascoeCEOBuy35,000$2.85$99,750.00View SEC Filing  
5/23/2013Rusty RayDirectorBuy5,000$2.85$14,250.00View SEC Filing  
5/23/2013Steven Robert MartinCFOBuy20,000$2.85$57,000.00View SEC Filing  
5/21/2013Kleanthis G XanthopoulosDirectorSell2,864$3.36$9,623.04View SEC Filing  
8/20/2012Edward M CoxVPBuy1,500$2.73$4,095.00View SEC Filing  
8/17/2012Rusty RayDirectorBuy4,000$2.81$11,240.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Apricus Biosciences (NASDAQ:APRI)
Latest Headlines for Apricus Biosciences (NASDAQ:APRI)
Source:
DateHeadline
reuters.com logoBRIEF-Apricus Biosciences says Armistice Capital reports a 9.6 pct passive stake in co
www.reuters.com - September 20 at 9:45 PM
reuters.com logoBRIEF-Apricus Biosciences announces $3.7 million private placement priced at-the-market
www.reuters.com - September 12 at 4:13 PM
seekingalpha.com logoApricus Biosciences (APRI) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 12 at 4:13 PM
globenewswire.com logoApricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market - GlobeNewswire (press release)
globenewswire.com - September 11 at 3:48 PM
finance.yahoo.com logoApricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market
finance.yahoo.com - September 11 at 3:48 PM
americanbankingnews.com logoHead to Head Survey: Apricus Biosciences (APRI) and Eyegate Pharmaceuticals (EYEG)
www.americanbankingnews.com - September 7 at 12:50 PM
finance.yahoo.com logoApricus, Topical Formulations Leading the Way, Q2 Review, and Outlook
finance.yahoo.com - September 6 at 3:56 PM
finanznachrichten.de logoApricus Biosciences, Inc.: Apricus Biosciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
www.finanznachrichten.de - September 5 at 5:37 PM
finance.yahoo.com logoApricus Biosciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 5 at 5:37 PM
seekingalpha.com logoPDUFA Run-Up Idea: Apricus Biosciences - Seeking Alpha
seekingalpha.com - September 4 at 4:28 PM
globenewswire.com logoApricus Biosciences Announces FDA Acknowledgement of Vitaros™ Class 2 NDA Resubmission - GlobeNewswire (press release)
globenewswire.com - August 31 at 3:52 PM
finance.yahoo.com logoApricus Biosciences Announces FDA Acknowledgement of Vitaros™ Class 2 NDA Resubmission
finance.yahoo.com - August 31 at 3:52 PM
seekingalpha.com logoApricus resubmits US marketing application for ED cream Vitaros - Seeking Alpha
seekingalpha.com - August 31 at 3:13 AM
americanbankingnews.com logoApricus Biosciences, Inc (APRI) Given a $5.00 Price Target at HC Wainwright
www.americanbankingnews.com - August 30 at 11:16 AM
finanznachrichten.de logoApricus Biosciences, Inc.: Apricus Biosciences Files NDA Resubmission for Vitaros™
www.finanznachrichten.de - August 30 at 2:17 AM
reuters.com logoBRIEF-Apricus Biosciences files NDA resubmission for Vitaros
www.reuters.com - August 30 at 2:17 AM
americanbankingnews.com logoApricus Biosciences, Inc (APRI) Expected to Announce Earnings of -$0.15 Per Share
www.americanbankingnews.com - August 29 at 10:26 PM
globenewswire.com logoApricus Biosciences Files NDA Resubmission for Vitaros™ - GlobeNewswire (press release)
globenewswire.com - August 29 at 4:16 PM
finance.yahoo.com logoApricus Biosciences Files NDA Resubmission for Vitaros™
finance.yahoo.com - August 29 at 4:16 PM
finance.yahoo.com logoETFs with exposure to Apricus Biosciences, Inc. : August 11, 2017
finance.yahoo.com - August 11 at 9:29 PM
americanbankingnews.com logo Brokerages Anticipate Apricus Biosciences, Inc (NASDAQ:APRI) to Post -$0.15 Earnings Per Share
www.americanbankingnews.com - August 11 at 4:44 PM
prnewswire.com logoDrug Makers Stock Performance Review -- DURECT, Sucampo Pharma, Apricus Biosciences, and MEI Pharma - PR Newswire (press release)
www.prnewswire.com - August 8 at 8:49 PM
americanbankingnews.com logoZacks Investment Research Lowers Apricus Biosciences, Inc (APRI) to Sell
www.americanbankingnews.com - August 4 at 11:16 PM
globenewswire.com logoApricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 4 at 3:29 AM
finanznachrichten.de logoApricus Biosciences, Inc.: Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results
www.finanznachrichten.de - August 3 at 5:25 PM
finance.yahoo.com logoEdited Transcript of APRI earnings conference call or presentation 2-Aug-17 8:30pm GMT
finance.yahoo.com - August 3 at 5:25 PM
americanbankingnews.com logoApricus Biosciences, Inc (NASDAQ:APRI) Announces Earnings Results
www.americanbankingnews.com - August 3 at 3:38 PM
nasdaq.com logoApricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results - Nasdaq
www.nasdaq.com - August 3 at 2:51 AM
rttnews.com logoEARNINGS SUMMARY: Details of Apricus Biosciences, Inc. Q2 Earnings Report
www.rttnews.com - August 2 at 9:49 PM
finance.yahoo.com logoApricus reports 2Q loss
finance.yahoo.com - August 2 at 9:49 PM
finance.yahoo.com logoApricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results
finance.yahoo.com - August 2 at 4:47 PM
globenewswire.com logoApricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call - GlobeNewswire (press release)
globenewswire.com - July 27 at 3:27 PM
nasdaq.com logoApricus Biosciences Announces Corporate Update and Second ... - Nasdaq
www.nasdaq.com - July 26 at 4:36 PM
nasdaq.com logoApricus Biosciences Announces Corporate Update and Second ... - Nasdaq
www.nasdaq.com - July 26 at 4:36 PM
finance.yahoo.com logoApricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call
finance.yahoo.com - July 26 at 4:36 PM
finance.yahoo.com logoApricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call
finance.yahoo.com - July 26 at 4:36 PM
americanbankingnews.com logoApricus Biosciences, Inc (NASDAQ:APRI) to Release Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:20 AM
americanbankingnews.com logoApricus Biosciences, Inc (NASDAQ:APRI) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - July 12 at 7:46 PM
prnewswire.com logoDaily Technical Summary Reports on Drug Makers Stocks -- Apricus Biosciences, DURECT, Sucampo Pharma, and ... - PR Newswire (press release)
www.prnewswire.com - June 28 at 4:09 PM
americanbankingnews.com logoApricus Biosciences, Inc (APRI) Expected to Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - June 28 at 8:06 AM
americanbankingnews.com logoApricus Biosciences Inc (APRI) Downgraded by Zacks Investment Research
www.americanbankingnews.com - June 27 at 9:34 PM
americanbankingnews.com logo-$0.17 Earnings Per Share Expected for Apricus Biosciences Inc (APRI) This Quarter
www.americanbankingnews.com - June 2 at 12:26 AM
americanbankingnews.com logoApricus Biosciences Inc (APRI) Short Interest Update
www.americanbankingnews.com - May 28 at 7:02 AM
prnewswire.com logoTechnical Reports on Drug Makers Stocks -- Synergy Pharma, Novo Nordisk, Apricus Biosciences, and - PR Newswire (press release)
www.prnewswire.com - May 22 at 8:03 AM
globenewswire.com logoApricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - May 13 at 3:39 PM
reuters.com logoBRIEF-Apricus Biosciences Q1 earnings per share $1.04
www.reuters.com - May 12 at 4:10 PM
finance.yahoo.com logoEdited Transcript of APRI earnings conference call or presentation 11-May-17 8:30pm GMT
finance.yahoo.com - May 12 at 4:10 PM
americanbankingnews.com logoApricus Biosciences Inc (APRI) Releases Earnings Results, Misses Estimates By $0.21 EPS
www.americanbankingnews.com - May 12 at 11:26 AM
nasdaq.com logoApricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results - Nasdaq
www.nasdaq.com - May 12 at 2:04 AM
rttnews.com logoEARNINGS SUMMARY: Details of Apricus Biosciences, Inc. Q1 Earnings Report
www.rttnews.com - May 11 at 9:03 PM

Social

Chart

Apricus Biosciences (APRI) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff